# Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)

> **NCT01081158** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 41 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)
- **DRUG:** Drug: SCH 900518 Biologic: Peginterferon alfa-2b
- **DRUG:** Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
- **DRUG:** Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)

## Key facts

- **NCT ID:** NCT01081158
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2015-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01081158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01081158, "Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01081158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*